This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised
by Zacks Equity Research
Merck beat Q2 earnings and sales estimates as strong oncology and newer products lift results, prompting the company to raise and narrow its 2026 sales outlook.
MRKPositive Net Change AZNPositive Net Change GILDNegative Net Change
biotechs medical pharmaceuticals vaccines
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
by Zacks Equity Research
Jazz Pharmaceuticals tops Q2 sales estimates and raises its 2026 revenue outlook despite an EPS miss, as strong oncology and neuroscience demand lifts shares.
JAZZNegative Net Change ABCLNegative Net Change HOWLNegative Net Change
biotechs earnings marijuana medical
INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook
by Zacks Equity Research
Indivior announces a merger with Supernus to form a CNS-focused biopharma company, tops Q2 earnings and revenue estimates and raises its 2026 outlook.
INDVPositive Net Change SUPNPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
by Zacks Equity Research
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
BAYRYPositive Net Change REGNPositive Net Change JNJPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Viatris Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.
VTRSNegative Net Change ACADPositive Net Change BBIONegative Net Change ARQTPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
CRSPNegative Net Change VRTXPositive Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs earnings
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus
by Zacks Equity Research
KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.
KRYSPositive Net Change NBIXNegative Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
by Zacks Equity Research
Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.
VRTXPositive Net Change CRSPNegative Net Change CRNXPositive Net Change
biotechs earnings
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
by Zacks Equity Research
Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
KROSNegative Net Change RGENPositive Net Change LQDAPositive Net Change HRMYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?
by Sundeep Ganoria
Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?
PFEPositive Net Change NVOPositive Net Change MRKPositive Net Change LLYPositive Net Change AMGNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines